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Summary To evaluate the utility of c-erbB-2, carcinoembryonic antigen (CEA) and CA 15.3 in the early
diagnosis of recurrence, serial serum determinations of these antigens were performed in 200 patients (follow-
up 1-4 years, mean 2.2 years) with primary breast cancer and no evidence of residual disease (NED) after
radical treatment (radical mastectomy or simple mastectomy and radiotherapy). Eighty-nine patients developed
metastases during follow-up. C-erbB-2, CEA and CA 15.3 were elevated (>20 U ml -, > 0 ng ml- or
>60 U ml-1 respectively) before diagnosis in 28%, 30% and 47% of the 89 patients with recurrence, with a
lead time of 4.5 +2.4, 4.9+2.4 and 4.8 +2.4 months respectively. Tumour marker sensitivity was clearly related
to the site of recurrence, with the lowest sensitivity found in locoregional relapse and the highest in patients
with liver metastases. When patients with locoregional recurrences were excluded, sensitivity improved: 31% (c-
erbB-2), 33% (CEA) and 56% (CA 15.3), with 76% having at least one of the three tumour markers. C-erbB-2
sensitivity in early diagnosis was significantly higher in patients with c-erbB-2 overexpression in tissue (8/10,
80%) than in those without overexpression (1/30, 3.3%) (P=0.0001). Likewise, higher levels of both, c-erbB-2
and CA 15.3 at diagnosis of recurrence, higher sensitivity in early diagnosis of relapse and a higher lead time
were found in PR+ patients (CA 15.3, P<0.0001) or in PR- patients (c-erbB-2, P=0.009). Specificity of the
tumour markers was 100% for all three markers (111 NED patients). In conclusion, c-erbB-2 is a useful tool
for early diagnosis of metastases, mainly in those patients with c-erbB-2 overexpression in tissue. Using all
three markers simultaneously it is possible to increase the sensitivity in the early diagnosis of recurrence by
11.2%.
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Several therapeutic methods have been tested to increase
survival in patients with breast cancer. It has been suggested
that early detection of relapse may improve survival. In the
case of relapse, treatment efficacy is, at least in theory, better
when diagnosis is made early (De Vita, 1983; Goldie, 1989).
For this purpose, specific tumour markers with high
specificity in relation to the diagnosis of relapse are
required. In patients with colon cancer, carcinoembryonic
antigen (CEA) serum levels have been recommended as an
aid to detect recurrent disease early (Minton et al., 1985). In
breast cancer CEA and CA 15.3 are the most commonly used
tumour markers (van Dalen, 1989; Colomer et al., 1989;
Molina et al., 1990, 1991; Alburquerque et al., 1995). The
usefulness of CEA and/or CA 15.3 for early detection of
recurrence in breast cancer is still unclear. Some authors have
indicated that elevations of CEA precede the onset of
clinically detectable metastatic disease, whereas others
disagree with this finding (Ahlemann et al., 1980; Chatal et
al., 1981; Coombes et al., 1981). Sensitivity of CEA and CA
15.3 in patients with metastatic breast cancer does, however,
suggest its possible role in the diagnosis of relapse. In a
previous prospective study, Molina et al. (1995) reported that
serial CEA and CA 15.3 serum evaluations in no evidence of
residual disease (NED) breast cancer patients provide a
simple and sensitive method for early detection of breast
cancer recurrence. These tumour markers have been shown to
detect 52% of relapses before clinical detection (chest
radiographs, liver ultrasonography and bone scans) with a
higher sensitivity for distant metastases (64%) and in patients
with ER' or PR' tumours.
The c-erbB-2 oncogene is overexpressed in approximately
20-30% of breast and ovarian carcinomas (Slamon et al.,
1989; Allred et al., 1992; Molina et al., 1992). Overexpression
of p185 c-erbB-2 seems to be related to more aggressive
tumours: higher histological and nuclear grade, histological
type (mainly in comedocarcinomas), higher duplication rate,
ER negativity and poor prognosis in breast carcinomas
(Slamon et al., 1989; Allred et al., 1992b; Molina et al., 1992).
Likewise, it has recently been indicated that a portion of c-
erbB-2, called plOO, may be found in the culture supernatant
of cell lines overexpressing this oncoprotein in the serum of
nude mice with tumours that overexpress c-erbB-2 and in
certain sera from patients with cancer (Zabrecky et al., 1991;
Pupa et al., 1993). However, few studies have been reported
in which serum was examined for the presence of a
circulating form of c-erbB-2 (Narita et al., 1992; McKenzie
et al., 1993; Molina et al., 1996).
This retrospective analysis assesses the usefulness of c-
erbB-2 for early diagnosis (before clinical evidence of disease)
of recurrence in patients with primary breast cancer and
compares it with that obtained using CEA and CA 15.3.
Material and methods
Serial c-erbB-2, CEA and CA 15.3 serum levels were
determined in 200 patients with primary breast cancer with
NED. A total of 1020 determinations of serum c-erbB-2,
CEA and CA 15.3 (mean 5.1 per patient) were performed. All
the patients in the study underwent radical mastectomy
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1996(98%) or simple mastectomy and radiotherapy (2%). The
presence of metastases was excluded (chest radiographs, bone
scans and liver ultrasonography) in all the patients included
in this protocol. Clinical examinations were performed every
3-6 months and chest radiographs, liver ultrasonography
and bone scans were done every 6-12 months. Likewise,
these complementary explorations were repeated on clinical
or analytical (abnormal serum levels ofc-erbB-2, CEA and/or
CA 15.3) suspicion of relapse. Relapse was diagnosed during
follow-up in 89 patients (locoregional 17, distant 72). In the
111 remaining patients there were no signs of relapse 12
months after the last serum evaluation.
C-erbB-2, CEA and CA 15.3 serum levels were determined
every 3-6 months. If elevated serum levels of one or other of
these tumour markers were observed, the same sample as well
as another obtained in the following 2 months were
evaluated. C-erbB-2, CEA and CA 15.3 serum levels were
considered as elevated when levels >20 U ml-',
> 10 ng ml-' or 60 U ml-' were detected in two sequential
determinations respectively. The use of these cut-offs for
abnormal levels resulted in high specificity; several reports
have indicated false-positive results in the lower ranges
(<10 ng ml-' or <60 U ml-' respectively) for benign
diseases as well as for NED patients (Molina et al., 1995,
1996). Elevations of c-erbB-2, CEA and/or CA 15.3 above
these values were considered as false-positive if no relapse
was diagnosed in the following 9 months after the
determination. Lead time was defined as the time interval
between elevation of the tumour marker (second sequential
measurement) and the diagnosis in months.
All samples were taken by venous puncture, centrifuged
and the serum frozen at -20°C until processed. C-erbB-2
protein in serum was determined using an enzyme-
immunoassay kit (Ciba Corning, Alameda, CA, USA) as
previously described (Molina et al., 1996). CEA and CA 15.3
were determined by a commercial enzyme-immunoassay
adapted to an ES-700 analyser (Boehringer Mannheim,
Germany). C-erbB-2 overexpression in tissue was determined
by immunohistochemistry using a standard avidin-biotin-
peroxidase complex (ABC) detection system. Briefly, 5-Mm
sections were cut from formalin-fixed paraffin-embedded
tissue blocks, foat-mounted on adhesive-coated glass slides,
deparaffinised and rehydrated. Slides were then sequentially
incubated, with intervening washes in Tris buffer (5 min), in
10% ovalbumin/10% normal goat serum to block non-
specific protein binding (20 min), 3% hydrogen peroxide/
0.1% sodium azide to quench endogenous peroxidase activity
(15 min), polyclonal antibody anti-c-erbB-2 at a dilution of
1:20 (2.5 h), byotinylated goat anti-rabbit secondary antibody
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(30 min), ABC (30 min) and 0.1% osmium tetraoxide to
enhance substrate (30 s). Slides were then counterstained with
methyl green (2 min), rinsed in deionised water, dehydrated
in graded alcohols, cleared in xylene and coverslipped with a
permanent mounting medium. A formalin-fixed breast
carcinoma was used as a positive control and included with
every batch processed. Immunostained slides were examined
by light microscopy by two observers and in cases of
discrepancy, revised. Samples displaying clear cytoplasmic
membrane staining in more than 5% of the malignant cells
were considered as positive. Oestrogen receptors (ERs) and
progesterone receptors (PRs) were determined in the primary
tumour of 174 patients. ER and PR were determined by a
receptor assay method, using charcoal-dextran for separation
and Scatchard plot for calculation. ER results greater than
5 fmol mg-' of cytosolic protein were considered as positive.
In 115 patients ER status was positive and in 59 it was
negative. PR results greater than 15 fmol mg-' of cytosolic
protein were considered as positive. In 100 patients PgR was
positive and in 74 it was negative.
For statistical calculations the Kolmogorov and chi-
square tests were used for qualitative results and the
Mann-Whitney U and Student's t-tests for quantitative
results (Altman, 1991). Sensitivity before diagnosis (persis-
tent rise of tumour markers with clinical examination,
radiography, CT scan or liver ultrasonography not
suggestive of relapse) or at diagnosis of recurrence
(clinically or by other procedures) was considered as the
ratio between the number of patients with relapse whose
marker levels were elevated over the total number of
patients with recurrence. Specificity was calculated by
dividing the number of NED patients with normal tumour
marker values by the total number of cases with NED.
Results
Elevated c-erbB-2 serum levels (>20 U ml-1) at diagnosis of
recurrence were found in 32.6% of patients with relapse.
None of the 111 NED patients had c-erbB-2 concentrations
higher than our suggested cut-off point. Abnormal CEA or
CA 15.3 serum levels were found in 41.6% (37/89) and 54%
(48/89) of patients with relapse (at diagnosis of recurrence)
respectively. CEA and CA 15.3 specificity for early diagnosis
ofrelapse was 100%. Significantly higher c-erbB-2, CEA and/
or CA 15.3 serum concentrations were found in patients with
relapse than in NED patients.
Tables I, II and III show the c-erbB-2, CEA and CA 15.3
results obtained in patients with relapse during the follow-up,
Table I C-erbB-2 serum levels before diagnosis (persistent rise ofc-erbB-2) and at diagnosis (clinically or by other procedures) in
patients with relapse during follow-up, subdivided according to steroid receptor status in the primary tumour and the site of
recurrence
Before diagnosis At diagnosis
No. ofpatients with No. ofpatients with
No. of elevated elevated
patients c-erbB-2a (%) c-erbB-2a (%) Median Range
Total 89 25 (28) 29 (32.6) 10.6 3-900
Locoregional 17 3 (17.6) 3 (17.6) 1ob 5-27.5
Bone 39 9 (23) 11 (28.2) lOc 3-56
Liver 12 6 (41.7) 7 (58.3) 22.7 5-91
Lung 15 6 (40) 6 (40) 15.8e 3-136
Others 6 2 (33.3) 2 (33.3) 7.1 5-900
ER+ 53 7 (13.2)f 11 (20.8)g 10 3-900
ER- 30 14 (46.7)" 14 (46.7)1 12.4 3-900
PR+ 46 6 (13Y 9 (19.6)" 10 3-900
PR- 37 15 (40.5)' 16 (43.2)m 13 3-900
Unknown ER 6 4 (66.7) 4 (66.7) 23.2 6- 54.5
and PR
aNo. of patients with abnormal C-erbB-2 serum levels (>20Umlr). b.c.dp=0.086; c,dp<0.05; b,c,d.ep<0.5 'hP=0.002 (chi-
square); g,ip=0.014 (chi-square); i"P=0.009 (chi-square); k,mp=0.036 (chi-square).C-erbB-2, CEA and CA 15.3 in early diagnosis of relapse
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Table II CEA serum levels before diagnosis (persistent rise of CEA) and at diagnosis of recurrence (clinically or by other procedures) in
patients with relapse during follow-up, subdivided according to the site of recurrence and the steroid receptor status in the primary tumour
Before diagnosisa At diagnosis
No. ofpatients with No. ofpatients with
No. of elevated elevated
patients CEAa (%) CEAa (%) Median Range
Total 89 27 (30.3) 37 (41.6) 6 1 -36
Locoregional 17 3 (17.6) 3 (17.6) 3b 2-41
Bone 39 11 (28.2) 16 (41) 7C 1-120
Liver 12 6 (50) 10 (83.3) 14.5 2-136
Lung 15 6 (40) 6 (40) 6e 2-54
Others 6 1 2 (33.3) 3.5 1-19
ER+ 53 15 (28.3) 22 (41.5) 6 1-136
ER- 30 10 (33.3) 13 (43.3) 5.5 1 -114
PR+ 46 13 (28.2) 20 (43.5) 7.5 1- 136
PR- 37 12 (32.4) 15 (40.5) 4 1 -114
Unknown ER 6 2 (33.3) 2 (33.3) 6 3-120
and PR
aNo. of patients with abnormal CEA serum levels (>IOngml-1). bcp= 0.007;bc.dp=0.002, c.dp 0.016;b.c,d,ep<0.05; dep<0.05.
Table III CA 15.3 serum levels before diagnosis (persistent rise of CA 15.3) and at diagnosis (clinically or by other procedures) in patients
with relapse during follow-up, subdivided according to the site of recurrence and the steroid receptor status in the primary tumour
Before diagnosis At diagnosis
No. ofpatients with No. ofpatients with
No. of elevated elevated
patients CA 15.3a (%) CA 15.3a (%) Median Range
Total 89 42 (47.2) 48 (54) 63 6-999
Locoregional 17 2 (11.8)b 4 (23.5) 23c 6-83
Bone 39 20 (51.2)d 23 (59) 87e 9 999
Liver 12 9 (75)f 9 (75) 1359 19-999
Lung 15 10 (66.7)h 10 (66.7) 1001 15-390
Others 6 1 2 (33.3) 25 12-250
ER+ 53 27 (51) 31 (58.5) 72 6-999
ER- 30 11 (36.7) 13 (43.3) 35 8- 390
PR+ 46 26 (56.5)3 29 (63) 92 6-999
PR- 37 12 (32.4)1 15 (40.5) 29m 8-390
Unknown ER 6 4 (66.7) 4 (66.7) 94 18 -256
and PR
aNo. of patients with abnormal CA 15.3 serum levels (>60UMml-). b.dp= 0.048 (chi-square); c.ep =0.004; b.c.d.ep.fP 0.0022 (chi-square); c.d.e.fp =0.028 (chi-square);b.c.d.e.fhp =0.0046 (chi-square);c.e.f.g.hp =0.003;ef,g.hp =0.006;c.e.f.g.hip =0.001;i'P<0.05 (chi-square); k.mp =0.0001.
Table IV Tumour marker sensitivity (%) in early diagnosis of recurrence (before clinical, radiography, CT scan, liver ultrasonography and
with nornal values of other tumour markers)
CA CEA-CA One or
Patient C-erbB-2 CEA CA 15.3 CEA -C-erbB-2 15.3-C-erbB-2 15.3 another
Locoregional 17 17.6 17.6 11.8 35.3 29.4 29.4 47
Bone 39 15.4 17.9 35.9 38.5 61.5 64.1 69.2
Liver 12 33.3 25 41.7 75 91.7 75 91.7
Lung 15 6.7 33.3 46.7 60 86.7 86.7 93.3
Others 6 33.3 0 16.7 50 50 16.7 50
ER+ 53 7.5 17 39.6 35.8 58.5 58.5 64.2
ER- 30 30 26.7 20 63.3 63.3 63.3 76.7
PR+ 46 6.5 17.4 39.1 37 60.8 63 67.4
PR- 37 27 24.3 24.3 56.7 59.5 56.7 70.3
Unknown ER 6 50 16.7 33.3 66.7 83.3 83.3 100
and PR
Total 89 18 20 32.6 47.2 62.9 59.6 70.8
subdivided according to the site of recurrence and the results
of steroid receptors (obtained in the primary tumour).
Persistently elevated c-erbB-2 levels were found before
clinical evidence of relapse or at the same time as clinical
evidence of recurrence in 28% and 32.6% of patients with
relapse respectively. CEA and CA 15.3 sensitivity for these
purposes were 30.3% and 47.2% for early diagnosis of
recurrence and 41.6% and 54% at diagnosis of recurrence
respectively. For early detection of recurrence the median
lead time was 4.5+2.4 months for c-erbB-2, 4.9+2.4 months
for CEA and 4.8+2.4 months for CA 15.3.
Tumour marker sensitivity in cases of early diagnosis of
recurrence and at diagnosis of recurrence was significantly
lower in patients with locoregional relapse than in those with
distant recurrence (P<0.001). The highest levels at diagnosis
as well as the highest sensitivity for early detection of relapseC-erbB-2, CEA and CA 15.3 in early diagnosis of relapse
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Table V C-erbB-2 sensitivity in early diagnosis and at diagnosis of recurrence subdivided according to c-
erbB-2 overexpression in tissue (immunohistochemistry)
Before diagnosis At diagnosis
C-erbB-2+a C-erbB-2_a C-erbB-2+a C-erbB-2_a
Locoregional 1/1 0/5 1/1 0/5
Bone 1/1 0/14 1/1 1/14
Liver 2/3 0/5 3/3 1/5
Lung 2/3 1/4 2/3 1/4
Others 2/2 0/2 2/2 0/2
ER+ 2/4 0/21 3/4 2/21
ER- 5/5 1/8 5/5 1/8
PR+ 1/3 0/19 2/3 1/19
PR- 6/6 1/10 6/6 2/10
Unknown ER or 1/1 0/1 1/1 0/1
PR
Total 8/10 80%b 1/30 3.3%c 9/10 90%b 3/30 9.3%C
aC-erbB-2 in the primary tissue. Positive: overexpression by IHC. bcp =0.0001.
were found in those patients with liver metastases (Tables I,
II and III). Higher CA 15.3 sensitivity, both at diagnosis of
relapse and at the time of early diagnosis of recurrence, was
found in PR' patients than in those with PR- status of the
primary tumour (P<0.001). Likewise, higher c-erbB-2
sensitivity was found in PR- patients than in PR' patients
(P=0.009).
Table IV compares the combined c-erbB-2, CEA and/or
CA 15.3 sensitivity in the early diagnosis of relapse,
subdivided according to the site of recurrence. C-erbB-2
was the first sign of recurrence (including other tumour
markers) in 18% of the patients with relapse. Similar results
were obtained with the CEA, being the first sign of
recurrence in 20% of the patients. CA 15.3 was the most
sensitive tumour marker, being the first sign of recurrence in
32.6% of the patients. The most sensitive combination of
tumour markers was obtained using c-erbB-2 and CA 15.3
(62.9%). At least one tumour marker was elevated before
diagnosis in 70.8% (63/89) of these patients. Exclusion of
patients with locoregional recurrence increased sensitivity to
76.4% (55/72) using all three tumour markers.
C-erbB-2 overexpression in tissue by immunohistochem-
istry was found in 22.5% of the 80 patients evaluated. Table
V shows c-erbB-2 sensitivity in serum subdivided according to
tissue overexpression. Significantly higher values at diagnosis
were found as well as a higher sensitivity in the early
diagnosis and at diagnosis of recurrence in patients with
tissue overexpression (P<0.0001). Only one patient without
tissue overexpression had abnormal c-erbB-2 serum levels
predating the diagnosis of recurrence. By contrast, c-erbB-2
in the early diagnosis was 80% in patients with over-
expression of this oncoprotein in tissue.
Discussion
About 50% of patients with breast cancer develop distant
metastases within 5 years after primary treatment. Detection
of metastatic disease seems to be an essential prerequisite for
successful therapy in these patients. Experimental studies
have shown higher response to treatment when a smaller
tumour mass is present (De Vita et al., 1983; Goldie, 1989).
Likewise, systemic drugs are used as adjuvant treatment for
breast cancer on the basis that therapy would theoretically be
more effective when the number of cells is the smallest
(Davidson and Lippman, 1988; Goldie, 1989). Many
radiological and physical scanning techniques are available
but these are expensive, time-consuming and usually do not
allow early diagnosis of relapse. Simplified detection of
metastases with specific tumour markers would facilitate the
follow-up and treatment of patients with breast cancer.
In a previous study Molina et al. (1995) reported that
CEA and CA 15.3 are useful tools in the early diagnosis of
recurrence. Serial increases of these tumour markers were the
first sign of recurrence in two out of every three patients with
distant recurrence. These results are similar to those reported
in smaller series (Ahlemann et al., 1980; Staab et al., 1980;
Chatal et al., 1981; Coombes et al., 1981) and indicate that
tumour marker determinations cannot replace other diag-
nostic procedures, but are useful tools in early diagnosis of
recurrence. There are no studies evaluating c-erbB-2 in the
early diagnosis of recurrence. Moreover, C-erbB-2 sensitivity
in patients with metastatic breast cancer suggest its possible
role in the early diagnosis of relapse (Narita et al., 1992;
McKenzie et al., 1993; Molina et al., 1996). In our experience
c-erbB-2 was the first sign of recurrence (before clinical
examination or another diagnostic method) and the first
tumour marker showing serial increases in 18%, CEA in 20%
and CA 15.3 in 32.6% of the patients with recurrence. The
most sensitive combination of tumour markers was obtained
using CEA and CA 15.3 (59.6%) or CA 15.3 and c-erbB-2
(62.9%). Likewise, using all three tumour markers, sensitivity
increased to 76.4% in patients with distant recurrence.
Treatment and survival of patients with breast cancer
relapse is directly related to the site of recurrence. Similarly,
tumour marker sensitivity for early diagnosis of recurrence is
related to the site of relapse. C-erbB-2, CEA and CA 15.3 are
not useful in the early diagnosis of locoregional recurrence
with clinical examination being the best detection method. In
contrast, one or other tumour marker allows early diagnosis
of metastases in 76.4% of NED patients, with a specificity of
100%. Similarly, tumour marker sensitivity in the early
detection of liver relapse is still greater, suggesting the
possibility of decreasing the frequency of physical scanning
techniques during the follow-up of NED patients.
The relationship between tumour markers in serum and
tissue with steroid receptor status has been reported
previously by our group (Molina et al., 1990, 1991, 1995).
In general, patients with well-differentiated tumours (ER+ or
PR+) had significantly higher serum CEA concentrations
than those without steroid receptors. Likewise, a higher rate
of CA 15.3 positivity has been detected by immunohisto-
chemistry in patients with ER+ (Kufe et al., 1984). Similar
results were found in this study, with higher CA 15.3
sensitivity for early detection of relapse in patients with
PR' tumours. In contrast, higher c-erbB-2 sensitivity was
found in both early diagnosis and at diagnosis of recurrence
in ER- or PR- tumours.
When using a parameter as a diagnostic tool, specificity is
more important than sensitivity. C-erbB-2, CEA and CA 15.3
are not specific tumour markers and several benign diseases
are associated with abnormal levels of these markers
(Colomer et al., 1989; Cases et al., 1991; Molina et al.,
1995, 1996). Six (5.3%) NED patients had elevated c-erbB-2,
three (3.2%) had elevated CEA and two (2.1%) had elevated
CA 15.3 when the classical cut-offs of 15 Uml-1 (c-erbB-2),C-erbB-2, CEA and CA 15.3 in early diagnosis of relapse
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5 ng ml-' (CEA) and 35 U ml-' (CA 15.3) were used. To
improve the specificity the cut-off levels were increased to
20 U ml-' for c-erbB-2, 10 ng ml-' for CEA and 60 U ml-'
for CA 15.3. Furthermore, positive samples were confirmed
by serial samples also showing elevated values. Using our
suggested cut-off points, tumour marker specificity during
follow-up increased to 100%. In summary, no patient had
abnormal levels of these tumour markers according to both
criteria without malignant disease.
C-erbB-2 sensitivity in both early diagnosis and at
diagnosis is lower than the sensitivity observed with CEA
and CA 15.3. These results are logical if we consider that
only 20-35% of the breast cancers overexpressed c-erbB-2 in
tissue. Theoretically, it is not possible to find abnormal c-
erbB-2 serum levels if there is no overexpression in tissue.
This theory has been confirmed in this study. C-erbB-2 was
useful in the early diagnosis of recurrence in 80% of the
patients with c-erbB-2 overexpression in tissue in contrast to
the sensitivity of 3.3% found in those patients without
overexpression. Similar results were found at diagnosis with
abnormal levels in 90% of the patients with overexpression in
contrast to the 10% found in those patients without it. It is
interesting to note that only slight increases of c-erbB-2
serum levels (the highest 25.3 U ml-1) were found in patients
with metastases and without overexpression of c-erbB-2 in
tissue. These results suggest that the increase in sensitivity
found by including c-erbB-2, CEA and CA 15.3 in the early
diagnosis of recurrence may be obtained by evaluating this
oncoprotein in only a third ofthe patients with breast cancer,
that is those with c-erbB-2 overexpression in tissue. In other
words, we increased the sensitivity in early diagnosis of
recurrence with c-erbB-2 serial determinations by 11.2% in
30% of the breast cancer patients.
Tumour markers seem to be useful tools in the early
diagnosis of recurrence. Another possible clinical application
may be as indicators of the need for initiating early
treatment. Several studies reported a duplication time of
about 2 months in mammary tumours (Silvestrini et al., 1974;
Goldie, 1989). A mean lead time of 4.9 months for early
diagnosis of recurrence indicates, at least in theory, a 4-fold
smaller tumour mass at detection and therefore also a higher
possibility of response to treatment (Silvestrini et al., 1974;
De Vita et al., 1983; Goldie, 1989). The use of tumour
marker serial determinations may allow the initiation of
systemic treatment with a theoretically higher probability of
response in 76.4% of the patients with distant recurrence.
However, the prognosis of patients with metastatic breast
cancer is poor, and the efficacy of this early treatment must
be evaluated. Our group is starting a randomised trial using
systemic treatment in those patients with a continuous
increase of tumour markers (excluding a second malignant
disease).
In summary, c-erbB-2 is a useful tumour marker in the
early diagnosis of recurrence (sensitivity 28%), mainly in
those patients with c-erbB-2 overexpression in tissue
(sensitivity 80%). The addition of c-erbB-2 in a protocol
using CEA and CA 15.3 increased the sensitivity in early
diagnosis by 11.2%. This sensitivity may be obtained using c-
erbB-2 serum levels only in patients with c-erbB-2 over-
expression in tissue. However, the long-term benefit of early
detection on therapy response and patients' survival remains
to be defined.
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